An amyloidosis diagnosis can take upwards of 2 years.Initial symptoms often are nondescript, and irreversible organ damage frequently occurs before disease confirmation.

Care of patients with systemic immunoglobulin light chain (AL) amyloidosis has undergone transformative changes, leading to marked, steady progress in outcomes for patients over the past four decades.

A drug that AstraZeneca singled out as one of its key potential revenue growth drivers in the next decade has failed a pivotal study in light chain amyloidosis, a rare disease with few treatment ...

BEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the European Commission (EC) has granted marketing authorisation for the expanded use of ...